There are currently 797 clinical trials in Indianapolis, Indiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Indiana University, Indiana University Melvin and Bren Simon Cancer Center, Riley Hospital for Children and Indiana University Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
NCT04571138
Recruiting
Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a chimeric antigen receptor (CAR). The CAR used in this study can recognize CD22, a protein expressed on the surface of leukemia and lymphoma cells. The phase 1 part of this study will determine the safety and appropriate dose level of these CAR T cell... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/06/2024
Locations: Riley Hospital for Children, Indianapolis, Indiana
Conditions: Leukemia, Lymphoma
Register for Updates
Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus
NCT05490511
Recruiting
The information learned in these studies will help to inform doctors as to how to appropriately adjust doses of cannabidiol and tacrolimus in order to improve health outcomes and long-term treatment success for transplant recipients.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/05/2024
Locations: IU Health University Hospital, Indianapolis, Indiana
Conditions: CBD, Transplant Complication, Kidney Disease, Chronic
Register for Updates
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Franciscan Health Indianapolis, Indianapolis, Indiana
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
DILIN - Prospective Study
NCT00345930
Recruiting
The purpose of this study is to identify individuals who have suffered a liver injury arising as an idiosyncratic reaction to a prescription drug or a complementary and alternative medicine. Recently added acute cases enrollment that meets criteria to the protocol. Also added Fibroscans to the protocol that will be completed at baseline and follow-up on chronic subjects.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/02/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Liver Diseases
Register for Updates
Drug-Induced Liver Injury (DILI) Network Retrospective
NCT00360646
Recruiting
The purpose of this study is to establish retrospectively a nationwide registry of patients who have suffered drug-induced liver injury (DILI), and to collect, immortalize, and store serum, DNA, and lymphocytes from these patients. ILIAD will serve as a resource for subsequent mechanistic investigations into the basis of severe idiosyncratic DILI. The primary goal of the ILIAD protocol is to create: (a) a clinical database consisting of individuals who have experienced severe DILI and the releva... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/02/2024
Locations: Indiana University, Indianapolis, Indiana
Conditions: Drug Induced Liver Injury
Register for Updates
CERAMENT™| Bone Void Filler Device Registry
NCT04244942
Recruiting
A device registry to compile data on the performance of CERAMENT BONE VOID FILLER in normal use.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Indiana University, Indianapolis, Indiana +1 locations
Conditions: Orthopedic Disorder
Register for Updates
Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers
NCT06182358
Recruiting
To compare the efficacy of XDEMVY ophthalmic drop to its vehicle control for the treatment of Demodex blepharitis and its impact on the soft contact lens wearing experience.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/22/2024
Locations: Site, Indianapolis, Indiana
Conditions: Demodex Blepharitis
Register for Updates
Macrowire for IntracraNial Thrombectomy
NCT06148675
Recruiting
The aim of this study is to develop a multicenter database of patient data and outcomes for patients undergoing intracranial thrombectomy for acute ischemic stroke secondary to emergent large vessel occlusion with delivery of reperfusion catheter over a novel macrowire (Aristotle Colossus) to perform intracranial mechanical thrombectomy.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/20/2024
Locations: Indiana University Methodist Hospital, Indianapolis, Indiana
Conditions: Stroke, Acute Ischemic
Register for Updates
CorMatrix Cor TRICUSPID ECM Valve Replacement - Pivotal Study
NCT05742906
Recruiting
The goal of this pivotal study is to demonstrate the safety and performance of the Cor TRICUSPID ECM (extracellular matrix) Valve (or Cor PEDIATRIC Tricuspid ECM Valve) for the surgical management of tricuspid valve disease and dysfunction in adult and pediatric patients. The main question(s) it aims to answer are: * whether the device may be implanted successfully and safely, and * whether the device effectively treats tricuspid valve disease and dysfunction through 12 months Participants wil... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/14/2024
Locations: St Francis Hospital, Indianapolis, Indiana
Conditions: Tricuspid Valve Disease, Tricuspid Valve Insufficiency
Register for Updates
Project 2 Airway Potential Hydrogen (pH) in Asthma
NCT03617718
Recruiting
This study is testing a non invasive way to measure airway pH in individuals with Asthma and Cystic Fibrosis using a new inhaled drug. The airway pH will help health care providers in creating tailored treatment plans for individuals suffering from these specific conditions.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
03/13/2024
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Cystic Fibrosis, Asthma, Severe Persistent Asthma, Healthy
Register for Updates
Hemlibra in Mild Hemophilia A
NCT04567511
Recruiting
This is a single arm, phase 4, prospective, open-label, United States single-center study to determine the hemostatic characteristics of Hemlibra (emicizumab) as measured by coagulation laboratory parameters in the mild hemophilia A male patient population with endogenous altered FVIII (baseline FVIII activity of \>5% to 30%). The safety and hemostatic efficacy of Hemlibra (emicizumab) in this patient population will be investigated. Secondary outcomes will assess changes in joint health and qua... Read More
Gender:
MALE
Ages:
Between 5 years and 45 years
Trial Updated:
03/13/2024
Locations: Indiana Hemophila @Thrombosis Center, Indianapolis, Indiana
Conditions: Factor VIII Deficiency, Congenital
Register for Updates
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
NCT04067336
Recruiting
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess ziftomenib, a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib will continue in patients with NPM1-m AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana
Conditions: Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia
Register for Updates